A Phase 3 interventional study of Ravulizumab and Pozelimab in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Regeneron Pharmaceuticals. Completed at 68 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals — 3 open to participants now, 3 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · Regeneron Pharmaceuticals.
Among the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, this one is one of 2 that started in 2022, is one of 5 in phase 3, and was the 5th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 48 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →3 of the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in Brazil, Canada, Italy and 4 more countries
Ages 18+
Regeneron Pharmaceuticals · Sites in Canada, Korea, Republic of, United Kingdom
Ages 18+
Regeneron Pharmaceuticals · Sites in Brazil, Canada, Colombia and 18 more countries
Ages 18+
By country, each count listing its studies:
Of the 29 Hemoglobinuria, Paroxysmal studies recruiting now, 13 (45%) set no upper age limit and 11 (38%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 5
First in 2019; this study’s year is marked. 2 started in 2022.
This study's enrollment of 202 is above the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 24 across the 9 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Regeneron Pharmaceuticals is the lead sponsor of 413 studies on the registry; 91 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 80 (63%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is researching a clinical treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on people with paroxysmal nocturnal hemoglobinuria (PNH). The aim of the study is to see how safe and effective the pozelimab + cemdisiran combination is for people with PNH and how the combination compares with 2 existing treatments: ravulizumab and eculizumab.
The pozelimab + cemdisiran combination may be referred to as "study drugs". Ravulizumab and eculizumab may also be called the "comparator drug".
The study is looking at several research questions, including:
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomized 1:1
Drug: Ravulizumab · Drug: Pozelimab · Drug: Cemdisiran
Randomized 1:1
Drug: Pozelimab · Drug: Cemdisiran · Drug: Eculizumab
Administered Intravenous (IV) per the protocol
Also known as: ALXN1210, Ultomiris
Administered IV and subcutaneous (SC) per the protocol
Also known as: REGN3918
Administered SC per the protocol
Also known as: ALN-CC5
Administered IV per the protocol
Also known as: Soliris
Percent change in lactate dehydrogenase (LDH)
Cohort A
Time frame: From baseline to week 26
Transfusion avoidance
Cohort B Not requiring a red blood cell (RBC) transfusion per the protocol
Time frame: From post-baseline day 1 through week 26
Adequate control of hemolysis
Cohort B LDH ≤1.5 × ULN at each visit
Time frame: From week 8 through week 26, inclusive
Maintenance of adequate control of hemolysis
Cohort A and B LDH ≤1.5 × ULN
Time frame: From week 8 through week 26, inclusive
Breakthrough hemolysis
Cohort A and B LDH ≥2 × ULN per the protocol
Time frame: From post-baseline day 1 through week 26
Adequate control of hemolysis
Cohort A LDH ≤1.5 × ULN
Time frame: From week 8 through week 26, inclusive
Hemoglobin stabilization
Cohort A and B Patients who do not receive an RBC transfusion and have no decrease in hemoglobin level per the protocol
Time frame: From day 1 (post-baseline) through week 26
Normalization of LDH
Cohort A and B LDH ≤1.0 × ULN per the protocol
Time frame: Between week 8 through week 26, inclusive
Transfusion avoidance
Cohort A and B Not requiring an RBC transfusion as per protocol algorithm based on post-baseline hemoglobin values.
Time frame: Day 1 through week 26
Change in fatigue as measured by the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale
Cohort A and B FACIT-Fatigue Scale is a 13-item, self-reported PRO measure assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health-related quality of life (QoL) in patients with cancer and other chronic illnesses. The FACIT-fatigue assesses the level of fatigue using a Likert scale ranging from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue.
Time frame: From baseline to week 26
Change in physical function (PF) scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)
Cohort A and B EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 7 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, sleep and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."
Time frame: From baseline to week 26
Change in global health status (GHS)/QoL scale score on the EORTC-QLC-C30
Cohort A and B EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 7 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, sleep and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."
Time frame: From baseline to week 26
Percent change in LDH
Cohort B
Time frame: From baseline to week 26
Rate of RBC transfused
Cohort A and B Per protocol algorithm
Time frame: Post-baseline Day 1 through week 26
Number of units of RBC transfused
Cohort A and B Per protocol algorithm
Time frame: Post-baseline Day 1 through week 26
Time to first LDH ≤1.5 × ULN
Cohort A and B
Time frame: Up to Week 26
Time to first LDH ≤1.0 × ULN
Cohort A and B
Time frame: Up to Week 26
Percentage of days with LDH ≤1.5 × ULN
Cohort A and B
Time frame: Between week 8 and week 26, inclusive
Change in hemoglobin levels
Cohort A and B
Time frame: From baseline to week 26
Incidence and severity of treatment emergent serious adverse events (SAEs)
Cohort A and B
Time frame: Up to 26 weeks
Incidence and severity of treatment-emergent adverse events (TEAEs) of special interest
Cohort A and B
Time frame: Up to 26 weeks
Incidence and severity of TEAEs leading to treatment discontinuation
Cohort A and B
Time frame: Up to 26 weeks
Change in total CH50
Cohort A and B
Time frame: From baseline to week 26
Percent change in total CH50
Cohort A and B
Time frame: From baseline to week 26
Concentration of total C5 in plasma
Cohort A and B
Time frame: Up to 60 weeks
Concentrations of total pozelimab in serum
Cohort A and B
Time frame: Up to 60 weeks
Concentrations of cemdisiran in plasma
Cohort A and B
Time frame: Up to 60 weeks
Concentrations of total ravulizumab in serum
Cohort A
Time frame: Up to 34 weeks
Concentrations of total eculizumab in serum
Cohort B
Time frame: Up to 30 weeks
Incidence of treatment emergent anti-drug antibodies (ADAs) to pozelimab
Cohort A and B
Time frame: Up to 60 weeks
Incidence of treatment emergent ADAs to cemdisiran
Cohort A and B
Time frame: Up to 60 weeks
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), the legal authority to share the data, and ensured the ability to protect participant privacy.
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Aug 2022 to primary completion in Sep 2026, 49 months.
Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 49 months is above that.
Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.
Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Sep 2026, on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.